Jump to main contents

Providing medical services for cardio-vascular disorders through regenerative medicine


[ Corporate Data ]

Name of the Company
Cardio Incorporated
Business Lines
Establishment of regenerative medicine for cardiovascular disorders through translational research encompassing cellular therapy, drug discovery, and tissue engineering.
October 2001
President, Yasuhiro Yanagi
2F, 1-5-5 Minatojimaminamimachi Chuo-ku, Kobe, Hyogo 650-0047 Japan
Tel: +81 (78) 304-6101
Fax: +81 (78) 304-6103
50.28 million yen (as of February 2014)
Number of executives and regular employees
6 (as of February 2014)
Corporate History
October 2001
Established as a campus venture company originating from the Osaka University Graduate School of Medicine.
March 2002
Met the qualifications set forth by the Law for Facilitating the Creation of New Business by the Ministry of Health, Labour and Welfare.
August 2002
Relocated our head office to Temma, Kita-ku, Osaka
December 2002
Capital increased to 145.8 million yen through a third-party allocation.
September 2003
Located Kobe TRI Laboratories in the Translational Research Informatics Center, one of the core facilities of the Kobe Medical Industry Development Project.
September 2004
Expanded Kobe TRI Laboratories.
March 2005
Capital increased to 498.3 million yen through a third-party allocation.
May 2005
Established Kobe BMA Laboratories.
February 2008
Capital reduced to 49.8 million yen.
February 2014
Capital increased to 50.28 million yen through a Exercising Share Option.
Back to main contents
Copyright (C) 2017, Cardio Inc. All rights reserved.